Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
about
Crizotinib resistance: implications for therapeutic strategiesTackling ALK in non-small cell lung cancer: the role of novel inhibitorsThe steady progress of targeted therapies, promising advances for lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCCIViC databaseFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCEmerging therapeutic agents for lung cancerPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceFusion gene and splice variant analyses in liquid biopsies of lung cancer patientsSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Ceritinib: A primer for pharmacists.The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCSecond-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.Resisting Resistance: Targeted Therapies in Lung Cancer.ALK: a tyrosine kinase target for cancer therapy.Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextIs there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis.The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Recent Advances in Targeting ROS1 in Lung Cancer.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.ALK alterations and inhibition in lung cancer.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Alectinib for ALK-positive non-small-cell lung cancer.The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.Updates in the management of brain metastases.
P2860
Q26738381-1A95B1F4-A879-46E1-935E-AB7E0B2719DAQ26740329-59D72B0C-6084-43D0-8F15-C27BB95A58B1Q26746895-0206AF33-E19C-4A16-83A9-1A8DD0CB1E51Q26747276-79D7AE53-9BB4-4735-A0E0-B1CA47212B34Q27612411-8F1B9BA8-437B-49F4-B4C7-567747B83651Q28068643-C83D429A-7F88-4AB8-8368-44ECBA7BEA6CQ28070165-5A9A0990-CD73-4869-A82A-7723ECB4AF72Q28071903-64592559-33A2-4B7B-8890-4B1C7623F7BFQ28079245-6994CBC2-752C-4AEB-8768-C07B96D5C92EQ30239901-0728DDC3-A668-44D6-9D84-43FEDE6047D5Q30244613-695C50FD-DE72-46FE-86C8-2B8F7B26A158Q33553447-8D0A442C-3354-4C45-B3E3-29530BD16BCDQ33591738-6B559F55-7078-4FC4-800A-6A6D3E0C9CA6Q33679543-9C00D68C-0ED3-425A-8887-2F402F599848Q33757138-4CCC5B63-8677-4D46-9985-AB9EE8A0D36CQ33791836-E8ED5A5F-AEB1-4091-BDA5-7E02E7F57E2CQ37121477-25B11B94-8FA9-46DE-BBFC-8EF0CB47CF18Q37209474-B9AF3DD7-0E73-4786-9C38-3E62E9AE2EB4Q37349315-AD7E41FA-80A8-4C1A-B4F0-9F16706DD550Q37388238-A477CC21-FF99-4922-AA17-A60D5397F6C0Q37518624-3D5229BA-E8AA-48FD-BB1C-2056F1B14386Q37584395-E6C6CC88-4F3D-47E1-898C-1367854EB734Q37669352-4C7CA1AF-B4D7-4B67-B743-4EF818894B81Q37697125-356D3EE5-5E56-4222-BF5B-C1706F41A070Q37737536-C37A0588-3E86-4562-A11B-8FF47484753DQ38631019-803F332A-D8EC-420D-B15E-B1377DAA33BDQ38640765-657D1FA7-84D5-4064-8CAA-5A0847A3BD8AQ38663460-55493DC5-7D96-46AF-8507-2623B5366E95Q38730915-F3A974F9-7986-4583-AAF5-67A4D14BC4B6Q38746336-7A824312-7418-4308-A8D7-61FAC36F76E9Q38763108-F62D9C4A-0B28-4D06-B1A8-775E0E1BD9F7Q38769610-911405CA-F6A9-4672-93A1-A0EEAD31B088Q38805618-B21BED2F-BE37-4F3A-B982-ED5BD290A1EBQ38816270-0D39DF70-AF81-486F-ADD9-A8656FD724F3Q38816700-0538C47B-EF37-49DB-A003-41FFCD6A57FEQ38820412-79666BB9-EEA7-48CA-99C2-9ED281662120Q38829087-19FA0ABF-1B56-4957-A68E-E53EBF987A35Q38846027-B26BD285-A04C-4F3A-A8C4-944773200E85Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0Q38887451-1D4508C7-A652-4929-827C-35FEAE0A0C95
P2860
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@ast
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@en
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@nl
type
label
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@ast
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@en
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@nl
altLabel
Activity and safety of ceritin ...... tre, open-label, phase 1 trial
@en
prefLabel
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@ast
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@en
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Activity and safety of ceritin ...... re, open-label, phase 1 trial.
@en
P2093
Alejandro Yovine
Alice T Shaw
Benjamin J Solomon
D Ross Camidge
Daniel S W Tan
Dong-Wan Kim
Gregory J Riely
Johan Vansteenkiste
Jürgen Wolf
Laura Q M Chow
P2860
P304
P3181
P356
10.1016/S1470-2045(15)00614-2
P577
2016-04-01T00:00:00Z